Aug. 8 Preclinical Quick Takes: Mayo Clinic assay for residual disease; plus camouflage for bacterial agents, Elicio's KRAS vaccine and more

Mayo Clinic liquid biopsy identifies breast cancer residual disease
A Mayo Clinic team reported in a Science Translational Medicine article that a personalized multiplex sequencing approach called TARDIS (targeted digital sequencing) could accurately distinguish pathological complete response and residual disease following cancer treatment by simultaneously detecting multiple patient-specific cancer mutations in circulating tumor DNA

Read the full 536 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE